A proposed new federal law could provide some competitive guardrails for the company's most important product.

Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Data from Structure Therapeutics and WAVE Life Sciences show that threats to the incumbents’ dominance are on the way.

It continues to be pounded by competition and challenges coming from numerous directions.

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...

FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from ...

The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...